Articles
19
All (19)
SCI-E, SSCI, AHCI (14)
SCI-E, SSCI, AHCI, ESCI (17)
ESCI (2)
Scopus (17)
TRDizin (3)
Other Publications (2)
13. ChatGPT's competence in responding to urological emergencies
ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY
, vol.31, no.3, pp.291-295, 2025 (SCI-Expanded, Scopus, TRDizin)
18. HOW IS THE EFFICACY OF PATIENT SELECTION CRITERIA FOR ADJUVANT PEMBROLIZUMAB AFTER CURATIVE SURGICAL TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA WITH INTERMEDIATE TO HIGH RISK OF RECURRENCE? A REAL-LIFE DATA ANALYSIS FROM SINGLE INSTITUTIONAL EXPERIENCE
THE JOURNAL OF UROLOGY
, vol.211,5, pp.436-437, 2024 (Conference Book)
Papers Presented at Peer-Reviewed Scientific Conferences
21
4. Radikal Sistektomi uygulanan kasa invaze mesane kanseri tanılı hastalarda preoperatif Nötrofil/Lenfosit oranı organa sınırlı hastalığı öngörebilir mi?
IURES 2025 Kongresi , Muğla, Turkey, 6 - 09 November 2025, pp.35-36, (Summary Text)
5. How is the efficacy of patient selection criteria for adjuvant pembrolizumab after curative surgery of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience
IURES 2025 Kongresi, Muğla, Turkey, 6 - 09 November 2025, pp.28-30, (Summary Text)
9. How is the efficacy of patient selection criteria of KEYNOTE 564 for adjuvant pembrolizumab after curative surgical treatment of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience
ESMO Congress 2025, Berlin, Germany, 17 - 21 October 2025, vol.36, pp.1423, (Full Text)
12. How is the efficacy of patient selection criteria for adjuvant pembrolizumab after curative surgical treatment of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience
16th European Multidisciplinary Congress on Urological Cancers (EMUC) 2024, Lizbon, Portugal, 7 - 10 November 2024, pp.262-263, (Full Text)
14. How Is The Effıcacy Of Patıent Selectıon Crıterıa For Adjuvant Pembrolızumab After Curatıve Surgıcal Treatment Of Clear Cell Renal Cell Carcınoma Wıth Intermedıate To Hıgh Rısk Of Recurrence? A Real-Lıfe Data Analysıs From Sıngle Instıtutıonal Experıence
American Urological Association's 2024 Annual Meeting, San-Antonio, Northern Mariana Islands, 3 - 06 May 2024, pp.436-437, (Full Text)
15. Fetal ürinomun postnatal dönemde renal fonksiyona etkisi: Üçüncü basamak tek merkez deneyimi
17. Türk Çocük Ürolojisi Kongresi, İstanbul, Turkey, 4 - 07 October 2023, (Summary Text)
16. Mesane Botryoid Rabdomyosarkomu: Multidisipliner Yaklaşımla İki Olgunun Yönetimi
17. Türk Çocük Ürolojisi Kongresi, İstanbul, Turkey, 4 - 07 October 2023, (Summary Text)
17. DMSA ASSESSMENT OF RENAL FUNCTION FOLLOWING MINI-PCNL
7th ISTANBUL UROLITHIASIS DAYS, İstanbul, Turkey, 02 December 2022, pp.41, (Summary Text)
20. Investigation of the Effect of Detrusor Muscle Presence on Results in Predicting Re-TUR Efficiency in Bladder Tumor
12th Eurasian Uro-oncology Congress, Erzurum, Turkey, 01 September 2022, (Full Text)
21. Mesane Tümöründe ReTUR Etkinliğini Araştıran Retrospektif Gözlemsel Bir Analiz
15. Ulusal Endoüroloji Kongresi, Girne, Cyprus (Kktc), 05 May 2022, (Full Text)
Books
2
2. Bladder and Urethral Injuries
in: Current Urology, 4th Edition, Ateş Kadıoğlu,Ozan Efesoy, Editor, TÜD/Türk Üroloji Akedemisi Yayını, İstanbul, pp.1083-1091, 2025
